FDA Asks ODAC To Ponder Shift Away From Single-Arm Studies

At its Feb. 8 meeting on issues surrounding confirmatory post-marketing studies, the Oncologic Drugs Advisory Committee will discuss whether and when randomized studies should be required to secure accelerated approval.